Last reviewed · How we verify
Zurita Laboratorio Farmaceutico Ltda. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Benzoyl peroxide and sulfur | Benzoyl peroxide and sulfur | marketed | Topical acne treatment combination | Dermatology | ||
| Vehicle of Acnase | Vehicle of Acnase | phase 3 | ||||
| Benzoyl Peroxide 5% and Sulphur 2% | Benzoyl Peroxide 5% and Sulphur 2% | phase 3 | Topical antimicrobial and keratolytic combination | Dermatology |
Therapeutic area mix
- Dermatology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- MedDerm Associates · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Zurita Laboratorio Farmaceutico Ltda.:
- Zurita Laboratorio Farmaceutico Ltda. pipeline updates — RSS
- Zurita Laboratorio Farmaceutico Ltda. pipeline updates — Atom
- Zurita Laboratorio Farmaceutico Ltda. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Zurita Laboratorio Farmaceutico Ltda. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zurita-laboratorio-farmaceutico-ltda. Accessed 2026-05-18.